CA-DEXCOM
2.2.2021 16:02:12 CET | Business Wire | Press release
DexCom, Inc . (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, debuted today its first-ever Super Bowl commercial , starring multi-platinum recording artist, actor and philanthropist Nick Jonas, who was diagnosed with Type 1 diabetes at the age of 13. The ad, which will run during Super Bowl LV on Feb. 7, 2021, calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005348/en/
“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best care, and that’s really the spirit of my first Super Bowl commercial. It means so much to me to bring this message of awareness and the need for improved CGM access to as many people with diabetes as possible.”
Tens of millions of people with diabetes around the world are still pricking their fingers, signaling a lack of awareness and the need to improve access for game changing CGM technology that has revolutionized diabetes management.
The Dexcom G6 CGM system uses a small wearable sensor and transmitter to measure and send real-time glucose values wirelessly to a compatible smart device or receiver,* eliminating the need for painful fingerpricks. † Dexcom CGM also displays trend arrows to show the speed and direction glucose levels are heading, making in-the-moment treatment decisions easier and helping people with diabetes avoid potentially dangerous high or low glucose events.‡
The ad, which will air at the end of the first quarter, shows how much various technologies have advanced over the last 40 years—contrasted by the realization that people with diabetes are still pricking their fingers to measure their glucose, a method invented in the 1970s.
“We are very excited to partner with Nick to shed light on technology that we know can significantly improve the lives of people with diabetes,” said Chad Patterson, senior vice president of global marketing for Dexcom. “People with diabetes deserve the best care, so along with leading diabetes advocacy groups, healthcare professionals and payers we are trying to increase awareness and improve access for CGM.”
As COVID-19 persists, Super Bowl parties are expected to look very different this year. For people with diabetes, a group at higher risk of COVID-19-related complications, social distancing and avoiding large gatherings is especially important. To help people feel less isolated on Super Bowl Sunday, Dexcom is giving fans the opportunity to “watch the game” with Nick Jonas through an interactive augmented reality experience.
Visit DexcomGameDay.com to see the commercial and find out how to watch the Super Bowl with Nick Jonas.
While the Super Bowl offers an enormous stage to launch this important conversation, Dexcom and Nick Jonas will be teaming up with leading diabetes nonprofits in the coming weeks to continue the discussion about better awareness, education and access for diabetes management technology. Organizations involved in this effort will include Beyond Type 1, the nonprofit co-founded by Nick, Children with Diabetes, College Diabetes Network, JDRF International and Taking Control of Your Diabetes.
To learn more about Dexcom CGM, visit Dexcom.com
About DexCom, Inc.
DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world. For more information, visit www.dexcom.com .
* For a list of compatible devices, visit www.dexcom.com/compatibility .
† If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
‡ The urgent low soon can warn you in advance of severe hypoglycemia—allowing you time to take appropriate action before it happens.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005348/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 20:36:00 CEST | Press release
A record-breaking sales value for a residential project in the UAEThe project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi1,700 residences sold within days after the launch15% non-UAE resident buyers81% new customers to Modon Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of laun
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release
Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized
Altasciences and Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough7.7.2026 15:00:00 CEST | Press release
Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025. The POC demonstrated the extension of AI-driven efficiencies from clinical reporting into nonclinical workflows, marking a significant step forward in accelerating drug development timelines. Building on proven results in clinical reporting, where the collaboration has achieved up to first-draft clinical study reports (CSRs), the teams have now successfully applied similar AI capabilities to nonclinical data through high-quality parsing of raw and SEND datasets in a proof-of-concept. This advancement aligns with the Altasciences Acceleration Platform, designed to fast-track drug development across the early-phase development continuum. “This milestone reflects the power of in
SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement7.7.2026 15:00:00 CEST | Press release
Building on live tokenized fund issuance and distribution capabilities, SS&C extends its innovation roadmap to support the next stage of digital investment markets SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets. As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
